NASDAQ:BEAT - BioTelemetry Stock Price, Forecast & News

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

BioTelemetry Inc (NASDAQ:BEAT) posted its earnings results on Tuesday, November, 5th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.02. The medical research company earned $111.30 million during the quarter, compared to analysts' expectations of $111.19 million. BioTelemetry had a net margin of 8.98% and a return on equity of 21.77%. The business's revenue was up 11.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.53 EPS. View BioTelemetry's Earnings History.

BioTelemetry is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for BioTelemetry.

6 Wall Street analysts have issued twelve-month price targets for BioTelemetry's shares. Their forecasts range from $54.00 to $87.00. On average, they anticipate BioTelemetry's stock price to reach $72.67 in the next twelve months. This suggests a possible upside of 39.7% from the stock's current price. View Analyst Price Targets for BioTelemetry.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTelemetry.

News coverage about BEAT stock has trended extremely negative on Sunday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioTelemetry earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for BioTelemetry.

Some companies that are related to BioTelemetry include Acadia Healthcare (ACHC), Hanger (HNGR), Biocorrx (BICX), AAC (AAC) and IMAC (IMAC).

Based on aggregate information from My MarketBeat watchlists, some companies that other BioTelemetry investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), ABIOMED (ABMD), Netflix (NFLX), Paypal (PYPL), Square (SQ), Adobe (ADBE), Advanced Micro Devices (AMD) and Twilio (TWLO).

BioTelemetry's stock is owned by many different of retail and institutional investors. Top institutional investors include Summit Creek Advisors LLC (0.98%), Scout Investments Inc. (0.56%), Strs Ohio (0.22%), State of Alaska Department of Revenue (0.08%), Curbstone Financial Management Corp (0.07%) and Tocqueville Asset Management L.P. (0.06%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry.

BEAT stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Louisiana State Employees Retirement System, State of Alaska Department of Revenue and Mesirow Financial Investment Management Inc.. Company insiders that have sold BioTelemetry company stock in the last year include Heather C Getz, Kirk E Gorman and Peter Ferola. View Insider Buying and Selling for BioTelemetry.

BEAT stock was purchased by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Summit Creek Advisors LLC, Strs Ohio, Assenagon Asset Management S.A., Exchange Traded Concepts LLC, Curbstone Financial Management Corp and New York State Teachers Retirement System. View Insider Buying and Selling for BioTelemetry.

Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BEAT stock can currently be purchased for approximately $52.02.

BioTelemetry has a market capitalization of $1.76 billion and generates $399.47 million in revenue each year. The medical research company earns $42.82 million in net income (profit) each year or $1.94 on an earnings per share basis. BioTelemetry employs 1,500 workers across the globe.View Additional Information About BioTelemetry.

The official website for BioTelemetry is http://www.gobio.com/.

BioTelemetry's mailing address is 1000 CEDAR HOLLOW ROAD, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected]